(Total Views: 407)
Posted On: 11/03/2017 7:04:16 PM
Post# of 15624
Re: GreenMachine84 #11293
The cost of a manufacturing plant for commercial quantities of a product is often far more than a fledgling biotech can afford. The majority of the companies either partner their, with the partner responsible for manufacturing, distribution and sales, or contract for those capabilities.
In OWCP's case, they already have Emilia geared up to make commercial quantities of the cream, I'm uncertain about the sublingual tablet. They have Mediq for German sales and distribution, and I believe they have options for the rest of Europe.
Certainly OWCP has much further room for growth in partnering it's products, but I believe we'll learn more after the Phase 1 trial results are known.
If in fact Mediq is able to put the cream on sale in German based on results of the trial, the stock should approach the billion dollar market cap on initiation of sales IMHO. That could occur by early next year if additional trials are not needed.
Gary
In OWCP's case, they already have Emilia geared up to make commercial quantities of the cream, I'm uncertain about the sublingual tablet. They have Mediq for German sales and distribution, and I believe they have options for the rest of Europe.
Certainly OWCP has much further room for growth in partnering it's products, but I believe we'll learn more after the Phase 1 trial results are known.
If in fact Mediq is able to put the cream on sale in German based on results of the trial, the stock should approach the billion dollar market cap on initiation of sales IMHO. That could occur by early next year if additional trials are not needed.
Gary
(1)
(0)
